Adaptimmune Therapeutics Plc (ADAPY)

0.0485 0.00 (0.00%) USD  |  OTCM  |  Dec 11, 16:00
More

Adaptimmune Therapeutics Research and Development Expense (Quarterly): 25.95M for June 30, 2025

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for ADAPY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Biodexa Pharmaceuticals Plc --
NuCana Plc 2.928M
Autolus Therapeutics Plc 27.72M
Mereo BioPharma Group Plc 4.244M
Bicycle Therapeutics Plc 65.65M